• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pediatr Blood Cancer . How we approach thrombosis risk in children with COVID-19 infection and MIS-C

tetano

Editor, Senior Moderator
Pediatr Blood Cancer


. 2021 May 6;e29049.
doi: 10.1002/pbc.29049. Online ahead of print.
How we approach thrombosis risk in children with COVID-19 infection and MIS-C


Anjali A Sharathkumar[SUP] 1 [/SUP], E Vincent S Faustino[SUP] 2 [/SUP], Clifford M Takemoto[SUP] 3 [/SUP]



Affiliations

Abstract

Thrombosis within the microvasculature and medium to large vessels is a serious and common complication among critically ill individuals with coronavirus disease 2019 (COVID-19). While children are markedly less likely to develop severe disease than adults, they remain at risk for thrombosis during acute infection and with the post-acute inflammatory illness termed multisystem inflammatory syndrome in children. Significant knowledge deficits in understanding COVID-19-associated coagulopathy and thrombotic risk pose clinical challenges for pediatric providers who must incorporate expert opinion and personal experience to manage individual patients. We discuss clinical scenarios to provide framework for characterizing thrombosis risk and thromboprophylaxis in children with COVID-19.

Keywords: COVID-19; MIS-C; anticoagulation; thrombosis.
 
Back
Top Bottom